Oncofid-P-B (paclitaxel-hyaluronic acid) in the intravesical therapy of patients affected by primary or recurrent Ta G1-G2 papillary cancer of the bladder. A phase II marker lesion study

Bassi, P.; Racioppi, Marco; Palermo, G.; Selli, Çiğdem; Battaglia, Michele; Simeone, C.; Eisendhardt, A.; Dorp, F. vom; Neisius, Andreas; Arjona, Manuel Fernández; Díaz, David Castro; Backhaus, M. Ramírez; Sierra, Jorge; Llorente, C.; Taurines, G. Nohales; Giordan, Nicola; Marinello, Arianna

doi:10.1016/s1569-9056(18)31567-7

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, HA–chemical drug conjugates for anticancer therapy have been actively investigated in clinical trials. Several types of anticancer chemical drugs including paclitaxel, irinotecan, doxorubicin, and 5-fluorouracil have been conjugated to HA, and their therapeutic effects have been assessed to treat various kinds of cancers such as the bladder, ovarian, breast, prostate, and metastatic lung cancers in preclinical/clinical trials. , Fidia Pharma Group reported that 6 weekly intravesical administration of Oncofid-P-B, paclitaxel–HA conjugate solution, resulted in the therapeutic effect for 45% of the patients with nonmuscle-invasive bladder cancer in phase II clinical trials last year . All these efforts will greatly contribute to the translational development of HA-based medicines.…”

Section: Translational Development Of Ha-based Medicinesmentioning

confidence: 99%

“…43,120 Fidia Pharma Group reported that 6 weekly intravesical administration of Oncofid-P-B, paclitaxel−HA conjugate solution, resulted in the therapeutic effect for 45% of the patients with nonmuscle-invasive bladder cancer in phase II clinical trials last year. 121 All these efforts will greatly contribute to the translational development of HA-based medicines.…”

Section: Ha-based Medicinesmentioning

confidence: 99%

See 1 more Smart Citation

Hyaluronic Acid Derivatives for Translational Medicines

Kim¹,

Shin

Han

et al. 2019

Biomacromolecules

View full text Add to dashboard Cite

The recent progress in various biomaterials with unique physiological and pharmacological properties has expedited the development of translational medicines for the diagnosis, prognosis, and therapy of intractable diseases. Hyaluronic acid (HA) is one of such biomaterials that has attracted great attention due to its unique characteristics for biomedical applications. In this Perspective, we provide an overview of HA-based medicines in a variety of forms such as chemical and biological conjugates, nanoparticles, nanoparticle hybrid systems, hydrogels, and nanogels. We highlight the current-state-of-the-art strategies to design and optimize innovative HA-based medicines for their clinical translations. Finally, we discuss the challenges for technical hurdles and the future directions to expand the feasibility of HA-based translational medicines.

show abstract

Section: Translational Development Of Ha-based Medicinesmentioning

confidence: 99%

Section: Ha-based Medicinesmentioning

confidence: 99%

Hyaluronic Acid Derivatives for Translational Medicines

Kim¹,

Shin

Han

et al. 2019

Biomacromolecules

View full text Add to dashboard Cite

show abstract

“…One of the ongoing trials, ONCOFID-P-B (paclitaxel-HA conjugate) is being studied in phase-III clinical trial to determine its effectiveness and safety in patients with Bacillus Calmette-Guérinunresponsive bladder cancer. [158,159] Similarly, in another recently completed trial HYMOVIS (partial hexadecylamide of HA conjugate, clear hydrogel) device was used to evaluate the beneficial effects for knee osteoarthritis. [160,161] Besides, with the exception of Declage (developed by LG Life Sciences in Korea) there is no commercially available drug delivery product based on HA, however, from the ongoing bioconjugation research efforts, it is expected that HA offers a great potential as a novel carrier with tunable biomimetic scaffold properties for various therapeutics interventions.…”

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

Hyaluronic Acid‐Based Bioconjugate Systems, Scaffolds, and Their Therapeutic Potential

Kotla

Isa

Larrañaga

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

In recent years, the development of hyaluronic acid or hyaluronan (HA) based scaffolds, medical devices, bioconjugate systems have expanded into a broad range of research and clinical applications. Research findings over the last two decades suggest that the abundance of HA in most mammalian tissues with distinctive biological roles and chemical simplicity for modifications have made it an attractive material with a rapidly growing global market. Besides its use as native forms, HA has received much interest on so‐called “HA‐bioconjugates” and “modified‐HA systems”. In this review, the importance of chemical modifications of HA, underlying rationale approaches, and various advancements of bioconjugate derivatives with their potential physicochemical, and pharmacological advantages are summarized. This review also highlights the current and emerging HA‐based conjugates of small molecules, macromolecules, crosslinked systems, and surface coating strategies with their biological implications, including their potentials and key challenges discussed in detail.

show abstract

“…Some of these systems have already entered clinical trials. Results from clinical trials with a paclitaxel–HA conjugate for the treatment of papillary non-muscle-invasive bladder cancer (NMIBC) were recently published by Bassi and co-workers [ 130 ]. The paclitaxel–HA conjugate used in this study was synthesized by activation of the hydroxy group of paclitaxel with carbodiimide for conjugation with 4-bromobutyric acid to form ester-linked 4-bromobutyric paclitaxel, which was conjugated to the carboxylic group of HA.…”

Section: Reviewmentioning

confidence: 99%

“…A higher rate of complete response was reported in patients not previously treated with chemo/immunotherapy. The probability to be free of recurrence after 3, 6, 9, and 12 months from the first drug administration was 98.2%, 96.4%, 74.4%, and 58.9%, respectively [ 130 ].…”

Section: Reviewmentioning

confidence: 99%

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

Geškovski¹,

Matevska-Geshkovska²,

Sazdovska³

et al. 2021

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

Nanomedicine has emerged as a novel cancer treatment and diagnostic modality, whose design constantly evolves towards increasing the safety and efficacy of the chemotherapeutic and diagnostic protocols. Molecular diagnostics, which create a great amount of data related to the unique molecular signatures of each tumor subtype, have emerged as an important tool for detailed profiling of tumors. They provide an opportunity to develop targeting agents for early detection and diagnosis, and to select the most effective combinatorial treatment options. Alongside, the design of the nanoscale carriers needs to cope with novel trends of molecular screening. Also, multiple targeting ligands needed for robust and specific interactions with the targeted cell populations have to be introduced, which should result in substantial improvements in safety and efficacy of the cancer treatment. This article will focus on novel design strategies for nanoscale drug delivery systems, based on the unique molecular signatures of myeloid leukemia and EGFR/CD44-positive solid tumors, and the impact of novel discoveries in molecular tumor profiles on future chemotherapeutic protocols.

show abstract

Oncofid-P-B (paclitaxel-hyaluronic acid) in the intravesical therapy of patients affected by primary or recurrent Ta G1-G2 papillary cancer of the bladder. A phase II marker lesion study

Cited by 5 publications

References 0 publications

Hyaluronic Acid Derivatives for Translational Medicines

Hyaluronic Acid Derivatives for Translational Medicines

Hyaluronic Acid‐Based Bioconjugate Systems, Scaffolds, and Their Therapeutic Potential

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

Contact Info

Product

Resources

About